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Marialuisa Bocchino, Alessandro Matarese, and Alessandro Sanduzzi
ABSTRACT. Treatment of latent tuberculosis infection (LTBI) is a key component in TB control strategies
worldwide. However, as people with LTBI are neither symptomatic nor contagious, any screening
decision should be weighed carefully against the potential benefit of preventing active disease in
those who are known to be at higher risk and are willing to accept therapy for LTBI. This means that
a targeted approach is desirable to maximize cost effectiveness and to guarantee patient adherence.
We focus on LTBI treatment strategies in patient populations at increased risk of developing active
TB, including candidates for treatment with tumor necrosis factor- blockers. In the last 40 years,
isoniazid (INH) has represented the keystone of LTBI therapy across the world. Although INH
remains the first therapeutic option, alternative treatments that are effective and associated with
increased adherence and economic savings are available. Current recommendations, toxicity,
compliance, and cost issues are discussed in detail in this review. A balanced relationship between
the patient and healthcare provider could increase adherence, while cost-saving treatment strategies
with higher effectiveness, fewer side effects, and of shorter duration should be offered as preferred.
(J Rheumatol Suppl. 2014 May; 91:71–7; doi:10.3899/jrheum.140105) 
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Latent tuberculosis infection (LTBI) is defined as an
infection with mycobacteria of the Mycobacterium tubercu-
losis complex, in which the bacteria are alive but not
currently causing active disease. Once infected, the chance
of a given immune-competent individual developing active
TB is highest within the first 2 years after exposure, with
half the cases occurring within 5 years, accounting overall
for the 5–10% of cases1. The remaining 90–95% of subjects
with LTBI stay healthy over their lifetime, representing the
largest reservoir of the tubercle bacilli. It is estimated that
about one-third of the world’s population has LTBI, the
majority of the cases being distributed in 22 high-burden
countries. Airborne infection control measures, with early
diagnosis and treatment of active TB, remain the top priority
to limit person-to-person transmission in resource-poor
countries in which the prevalence of TB is high2. Although
treatment of LTBI is an essential component of TB control
in low-prevalence countries such as the United States,
where a significant proportion of cases of active TB is due
to reactivation of an old infection3, it is not widely practiced
in most endemic countries. 
Targeting LTBI Treatment 
Because people with LTBI are neither symptomatic nor
contagious, any screening decision should be weighed
carefully against the potential benefit of preventing active
disease in those who are known to be at higher risk and are
willing to accept therapy for LTBI. A targeted approach is
therefore desirable to maximize cost-effectiveness.
Treatment of contacts should be tailored on the basis of risk
assessment algorithms that consider a range of factors,
including type of contact (close or casual), tuberculin skin
test (TST) and/or interferon- release assay (IGRA) results,
bacillus Calmette-Guérin vaccination status, place of birth
(foreign-born or resident), and age group (cutoff 35 yrs).
Current guidelines suggest treatment in recently infected
cases due to close exposure to patients affected by active
pulmonary TB. Additional high-risk populations are
reported in Table 14,5. The targeted policy comprises no
therapy in casual contacts with a positive vaccination
history even with a positive TST result6. Conversely,
treatment of LTBI must be offered to individuals infected by
human immunodeficiency virus (HIV), foreign-born
subjects younger than 35 years, immune-suppressed
patients, and children under the age of 5 years with a recent
contact with a case of active TB regardless of TB infection
screening results6,7.
It is mandatory that before starting any treatment, active
TB should be carefully excluded in all cases. All close
contacts (household, close friends, and job colleagues) of
patients with active TB and vulnerable subjects (cases with
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1 or more known TB risk factors) must be offered a chest
radiograph and a screening test for TB infection (that is,
TST and/or any IGRA). All cases tested positive by the TST
and/or IGRA with no evidence of clinical and radiographic
signs suggestive of active TB should be treated for LTBI. In
the case of suspicion of a false-negative TST and/or IGRA
result, retesting should be considered after a window period
of at least 8 weeks from the last exposure to the index case
while still infectious8,9. In the case of suspicion of active
TB, the patients should have 3 daily sputum specimens (or
additional site-specific samples, if requested) cultured for
mycobacteria. Further investigations should be tailored
based on the clinical and radiological presentation. 
Therapy Options 
Current standard monotherapy with daily self-administered
isoniazid (INH) is the preferred regimen in the United States
and European countries because it reduces the risk of active
TB by as much as 90% if taken for 9 months10,11. Pros-
pective randomized controlled trials (RCT) have largely
established the protective efficacy of INH given for 6–12
months among both non-HIV-infected and HIV-infected
subjects12,13. A 6-month (m) regimen also provides
protection, being more favorable from a cost-effectiveness
point of view11. Pina, et al found that the number of patients
to be treated to prevent 1 TB case was 33 and 26, using
6m-INH or 9m-INH, respectively, with an estimated cost
ratio of 0.98 (95% CI 0.6–1.5)14. Shortening the treatment
duration to 6 months is actually recommended in
immune-competent adults11,15. Intermittent INH therapy
(i.e., twice weekly with increased dosage) is allowed as
directly observed treatment. Longterm INH therapy may be
an effective and quite safe option in HIV-infected patients in
high TB-burden settings16.
Daily rifampicin (RMP) monotherapy for 24 weeks is
well tolerated17, but efficacy data are currently
limited18,19,20, and concerns remain over possible selection
of RMP-resistant mutants in HIV-infected patients receiving
antiretroviral therapies21. With an assumed 4m-RMP
efficacy of 60%, this regimen has been estimated to be
cheaper and more effective than 9m-INH, offering a
challenge to cost savings within 10 years along with a
significant reduction in the risk of noncompletion and liver
toxicity22,23. Treatment with RMP alone is indicated for
people who cannot tolerate INH, or close contacts of
patients affected by INH-resistant TB10.
Combination therapy with RMP and pyrazinamide (PRZ)
for 2 months, given either daily or twice weekly, was
advocated as an alternative choice in the American Thoracic
Society (ATS)/US Centers for Disease Control (CDC)
guidelines in 200010. Despite the initial promising results in
HIV-infected patients24,25, further reporting of severe liver
toxicity and death mainly in non HIV-infected patients26,27,
as confirmed later in a metaanalysis by Gao, et al28, led to a
revision of the ATS/CDC recommendations in 200329. As a
consequence, this regimen should not generally be offered.
In selected cases (patients poorly compliant to longer
therapies or intolerant to INH), clinical surveillance and
liver function monitoring are required.
Daily or intermittent combined treatment with RMP plus
INH for 3 months has proven efficacy, is well tolerated, and
is safe30,31; however, adverse effects (AE) may be more
frequent than with monotherapy regimens32. Salinas, et al
recently reported an increased rate of treatment completion
(84.9% vs 92.5%) and lower hepatotoxicity (1.6% vs 2.4%)
in patients treated with 3m-RMP/INH in comparison with
6m-INH33.
Three RCT have shown that a new combination regimen
of INH and rifapentine (RPT) administered weekly for 12
weeks as directly observed treatment is as effective at
preventing TB as other regimens32,34. Sterling, et al reported
that active TB developed in 7 of 3986 subjects in the combi-
nation-therapy group (cumulative rate, 0.19%) and in 15 of
3745 subjects in the INH-only group (cumulative rate,
0.43%), for a difference of 0.24 percentage points. Rates of
treatment completion were 82.1% and 69.0%, respectively
(p < 0.001), with the proportions of drug discontinuation
due to an AE being 4.9% and 3.7%, respectively (p = 0.009).
Rates of investigator-assessed drug-related hepatotoxicity
were 0.4% and 2.7%, respectively (p < 0.001)35. The CDC
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Table 1. Risk factors for progression of latent tuberculosis (TB) infection into active disease.
■ Recent close exposure to active pulmonary TB (within 2 years) 
■ Human immunodeficiency virus infection  
■ Recently exposed infants and children aged < 5 years  
■ Silicosis  
■ Radiographic findings consistent with prior untreated or not adequately treated TB  
■ Immigrants from high TB burden areas  
■ Residents and employees of congregate living facilities  
■ Solid organ transplantation/solid organ tumors (neck, head, lung)/lymphoma, leukemia  
■ Gastrectomy/jejunoileal bypass  
■ Chronic renal failure/hemodialysis  
■ Diabetes mellitus/low body mass index (< 18.5)  
■ Longterm therapies with corticosteroids/immunosuppressive drugs or with tumor necrosis factor- blockers  
■ Cigarette smokers/drug or alcohol abusers  
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recommends this regimen as an equal alternative to the
9m-INH regimen for otherwise healthy patients aged ≥ 12
years who have LTBI and factors that are predictive of the
development of TB (e.g., recent exposure to contagious TB).
The new regimen can also be considered for other categories
of patients when it offers practical advantages. Although the
INH-RPT regimen was well tolerated in treatment trials,
monitoring for AE is recommended36. RPT-based regimens
for treating LTBI are being considered for future clinical
trials, but even if they prove effective, high drug costs may
limit their economic viability. Holland, et al have estimated
that both daily INH/RPT for 1 month and weekly INH/RPT
for 3 months were less expensive and more effective than
other strategies under a wide variety of clinically plausible
variable estimates, the former being the least expensive and
most effective37. Current treatment regimens with their
doses/schedules are reported in Table 2. 
Management of Suspected Drug-resistant LTBI 
Expert opinions differ on whether to treat contacts of
patients with multidrug-resistant TB. A reasonable option
may be close clinical monitoring for at least 2 years for
contacts who are healthy and do not have risk factors for
disease progression. Regarding treatment, further concerns
that have not yet been resolved include the choice and
number (at least 2) of drugs to be used, and for how long.
Regarding this issue, the 2000 ATS/CDC guidelines
recommend combining PRZ with ethambutol or with a
quinolone (i.e., levofloxacin or ofloxacin) for 6–12 months,
respectively, in immune-competent and HIV-infected
contacts10. However, poor tolerance and high rates of liver
toxicity have been observed with PRZ-containing
regimens38,39,40. Fluoroquinolone monotherapy has been
suggested as a safe alternative, but emergence of drug
resistance is a matter of concern41. More recently, thiori-
dazine alone, or with other antibiotics, has been proposed
for the treatment of drug-resistant LTBI as inexpensive,
effective, safe, and unlikely to induce resistance42. In a
computerized Markov model assessing the cost and effec-
tiveness of 6 different therapy options, the combination of
moxifloxacin with ethambutol was estimated as the
preferred strategy under a wide array of assumptions43. 
Toxicity Issues 
Hepatotoxicity is the most severe AE related to LTBI
treatment. Drug administration should be discontinued if
transaminase levels are greater than 3 times the upper limit
of normal in symptomatic patients or 5 times the upper limit
of normal in asymptomatic patients. In a retrospective study
done from 1999 to 2005 among 219 adults patients initiating
INH treatment, Vinnard, et al found that 8% of cases discon-
tinued therapy because of liver toxicity, the median time to
onset of this toxicity being 3 months44. Discontinuation was
not associated with advancing age, while a predictive factor
was hepatitis C infection. Conversely, in a retrospective
evaluation of 11 studies addressing this issue in the general
population (n = 6) and in transplant recipients (n = 5),
chronic viral hepatitis was not an established risk factor for
INH hepatotoxicity45. In a further analysis of a historical
cohort including all residents given therapy for LTBI (95%
INH, 5% RMP) in Quebec, the risk of hepatotoxicity
requiring hospital admission increased significantly among
patients over 65 years old46. Previously, in a systematic
review including 7 studies (18,610 participants), the rates of
INH- and/or RMP-associated liver injury were higher among
persons aged ≥ 35 years47. Recently, based on data in a
passive surveillance system, the CDC reported the occur-
rence of 17 serious AE in INH-treated patients (15 adults and
2 children) in the period 2004–2008, suggesting the need for
liver function monitoring while receiving therapy48.
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Table 2. Treatment regimens and doses/schedules of latent tuberculosis (TB) infection.
Regimen                                                   Dose/Schedule                                                                       Recommendation  
Isoniazid for 9 mos                                  Daily, self-administered 5 mg/kg (max 300 mg/day)           ATS/CDC, preferred regimen for all risk groups
                                                                  Twice weekly, DOT 15 mg/kg (max 900 mg/dose)              
Isoniazid for 6 mos                                   Same dose/schedule of INH-9 months                                  NICE (UK), recommended regimen for 
                                                                                                                                                                 HIV-infected/uninfected people of any age
Rifampicin for 4 mos                               Daily, self-administered 10 mg/kg (max 600 mg/day)          Alternative to INH 9 mos for contacts of 
                                                                                                                                                                 INH-resistant TB
Rifampicin plus isoniazid for 3 mos        Daily, self-administered RMP: 10 mg/kg (max 600             NICE (UK), equal alternative to INH 6 mos for
                                                                  mg/day); INH: 5 mg/kg (max 300 mg/day)                          non-HIV adults  
Rifapentine plus isoniazid for 3 mos       Once weekly, DOT; INH: 15 mg/kg (max 900 mg/dose)     CDC, equal alternative to self-administered 
                                                                  RPT:                                                                                       9m-INH in persons ≥ 12 yrs. Not recommended 
                                                                  10.0–14.0 kg: 300 mg                                                            for children < 2 yrs, HIV-infected persons taking ART,    
                                                                  14.1–25.0 kg: 450 mg                                                           pregnant women
                                                                  25.1–32.0 kg: 600 mg    
                                                                  32.1–49.9 kg: 750 mg    
                                                                  ≥ 50 kg: 900 mg max   
INH: isoniazid; RMP: rifampicin; RPT: rifapentine; ART: antiretroviral therapy; ATS: American Thoracic Society; CDC: US Centers for Disease Control and
Prevention; NICE: UK National Institute for Health and Clinical Excellence; DOT: directly observed treatment; HIV: human immunodeficiency virus.
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A metaanalysis of 4 RCT comparing conventional INH
treatment with the association of RMP/PRZ in 2657
HIV-infected patients showed that the rate of development
of severe hepatotoxicity was lower in the RMP/PRZ group
than in the 6–12m-INH group49. A combined clinical picture
of INH-induced eosinophilic exudative pleural effusion 
and systemic lupus erythematosus was also found in a 
75-year-old woman50. Finally, AE, including low rates of
hepatotoxicity, flu-like syndrome, and thrombocytopenia,
have been reported in 87 patients under LTBI treatment with
RMP, with 2 cases developing active TB during 21.8 months
of followup51. Negligible rates of hepatotoxicity were
reported in 205 adults with LTBI treated with RMP who had
poor adherence to clinic visits and treatment52. Four months
of treatment with RMP was associated with significantly
better completion rates and less hepatotoxicity, albeit at a
higher total cost53. 
Compliance 
Although INH reduces the risk of active TB by as much as
90% if taken daily for 9 months, acceptance and adherence
to prolonged therapy are less than desired because
completion is less than 50% in many programs. The
relationships between medication adherence and demo-
graphics, sex, self-reported health, and side effects are
inconclusive54,55.
Of 101 household contacts of hospitalized patients with
pulmonary TB in Brazil, 53.5% completed a 6m-INH
regimen, the risk of treatment noncompletion being signifi-
cantly higher in household contacts who reported side
effects; 28.7% of cases were lost to followup because of
difficulties reaching the hospital56. A previous survey study
including 380 LTBI patients attending the Wetmore TB
Clinic (New Orleans, Louisiana, USA) estimated that the
adherence rate to treatment was very low, at 19%57. A more
comprehensive systematic review of 78 studies in the
United States and Canada, published between 1997 and
2007, found suboptimal adherence and completion rates
across high-risk groups, with no consistent associations with
patient-related factors, clinic facilities, or treatment charac-
teristics58. Completion rates of 59% and 67% were reported
for 9m-INH and 6m-INH regimens, respectively, in a retro-
spective review of pharmacy records from 2000 to 200659.
A completion rate of 45.2% was estimated in New York City
among a total of 15,035 patients. Treatment completers were
more likely to be 35 years old or more, contacts of patients
with pulmonary TB, receiving directly observed treatment,
and to have received the RMP-based regimen, with no
differences between HIV-negative and HIV-positive
individuals60. In a retrospective survey in 19 regions of the
United States and Canada, the risk factors for failure to
complete treatment included starting the 9m-INH regimen,
residence in a congregate setting (nursing home, shelter, or
jail), injection drug use, age 15 years or more, and employ-
ment at a healthcare facility61. In a randomized prospective
study by Trajman, et al treatment completion was higher
with RMP than with the conventional INH regimen. Early
predictors of nonadherence were late first visit attendance, >
20% of missed doses, and greater variation of hours between
doses. Serious AE were not associated with irregularity of
treatment62. Marriage and alcohol use were significant
predictors of completion and noncompletion in 2 RCT
comparing 6-12m-INH to 9m-INH self-administered
regimens, with an overall treatment adherence rate of
44%63. A further retrospective evaluation including 599
LTBI cases in Spain found a very high rate of treatment
completion (80.8%), with no differences accord ing to
therapy duration. Again, low adherence was associated with
age < 36 years, male sex, immigrant status < 5 years of
residence, and the presence of social risk factors64.
LTBI Management in Candidates for Tumor Necrosis
Factor- Blockers 
Although there is wide agreement among scientists and
experts about the need to treat LTBI in candidates for
anti-tumor necrosis factor- (TNF-) therapy, the choice of
the best timing for initiation is still a matter of debate. In the
United States, the CDC suggest completing LTBI therapy
before starting treatment with TNF- blockers65. 
Conversely, in the European setting, the current
opinion is to start anti-TNF- treatment at the completion
of an induction period of 3–8 weeks of LTBI therapy;
both treatments can then be continued together for the
required period66,67,68. More recently, a board of experts
fixed the so-called induction period of LTBI therapy at 4
weeks69. 
Treatment management of LTBI is largely based on INH
monotherapy at the dosage of 5 mg/kg per day for 9 months.
This is also the safest regimen in terms of occurrence of
hepatotoxicity and of other AE70. An increased rate (39%)
of gastrointestinal intolerance or high transamine levels was
recently reported in a small cohort of patients treated with
INH or RMP while taking antirheumatic drugs71.
Currently no regimens have been validated as alterna-
tives to INH for LTBI treatment in this specific clinical
setting. However, further options may be represented by the
daily or intermittent association of INH and RMP, or by
RMP monotherapy in INH-intolerant patients.
In the last 40 years, INH has been the keystone of LTBI
treatment in all clinical settings, with few alternative and
equally effective options available. Targeted testing of
high-risk populations is pivotal in TB control programs as
“intention to test is intention to treat.” A balanced
relationship between patients and the healthcare provider
could increase adherence, while cost-saving treatment
strategies with greater effectiveness, fewer side effects,
and shorter duration should be offered as consistently
preferred. 
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In summary: 
LTBI screening and treatment decisions should be
weighed carefully against the benefit of preventing
active disease in high-risk patients 
Longterm administration of INH has been the keystone
of LTBI therapy over the last 40 years 
Effective, well-tolerated, shorter lasting, and
cost-saving alternative therapy regimens are becoming
available
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